pharmaceutical investing Revive Therapeutics Announces Submission of IRB Approval for Phase 3 Clinical Trial Protocol for Bucillamine in COVID-19
pharmaceutical investing Revive Therapeutics Provides Corporate Update on its Pharmaceutical Initiatives
pharmaceutical investing Revive Therapeutics Provides an Update on its Psilocybin-Based Pharmaceutical Program
pharmaceutical investing Revive Therapeutics Announces U.S. FDA Recommendation to Proceed Directly Into A Phase 3 Confirmatory Clinical Trial
pharmaceutical investing Revive Therapeutics Announces Research Partnership Agreement with the University of Wisconsin-Madison
pharmaceutical investing Revive Therapeutics Partners with Complete Phytochemical Solutions to Advance Research Initiatives for Psilocybin-Based Pharmaceutical Products
pharmaceutical investing Revive Therapeutics Announces Closing of Second Tranche of Brokered Private Placement
pharmaceutical investing Revive Therapeutics Engages Novotech as Asia-Pacific CRO for Bucillamine in the Treatment of Infectious Diseases
cannabis investing Revive Therapeutics Provides Corporate Update on its COVID-19 and Infectious Diseases Programs
pharmaceutical investing Revive Therapeutics Appoints Dr. David Boulware, MD, as Scientific Advisor for Infectious Diseases including COVID-19
cannabis investing Revive Therapeutics Explores the use of Bucillamine as a Novel Treatment for Infectious Diseases Including COVID-19
Right to Earn Majority Interest in Highly Prospective Chilean Copper-Gold-Molybdenite Porphyry Project and Placement to raise $2.2m
